DMF Medical's memsorb‚Ñ¢ Receives Health Canada Approval on All Major Anesthesia Platforms in Canada

DMF Medical Incorporated, a privately held medical device company, is pleased to announce it has received a Class II medical device license from Health Canada to sell its memsorb‚Ñ¢ carbon dioxide (CO2) filtration device for general anesthesia in the Canadian market on all major platforms.

memsorb‚Ñ¢ is now available for sale for use on Drager Fabius, Primus, Perseus and Zeus and the GE Aisys machines.

DMF's goal has always been making anesthesia safer and now they are one step closer to making that goal a reality, starting in Canada.

Dr. David Roach, president, and Dr. Michael Schmidt, chief medical officer, would like to thank the company's clinical advocates nationally and internationally for their enthusiasm and tenacity in pursuing device evaluations even in the face of significant challenges posed by COVID-19.  

The cooperation and collaboration with sites across the country, in particular London Health Sciences Centre in London, Ont., and Hôpital Maisonneuve Rosemont in Montreal speaks to the level of commitment the Canadian health-innovation community has for improving health care in anesthesia while focusing on reducing its impact to the environment.

About memsorb‚Ñ¢
memsorb‚Ñ¢ is a next-generation CO2 removal system for general anesthesia. It uses patented medical membrane technology rather than a chemical reaction to remove CO2 from the breathing circuit of anesthesia machines. memsorb‚Ñ¢ provides numerous advantages over current technologies including: longer life, elimination of waste, reduced greenhouse gas emissions, elimination of chemical byproducts, and increased machine reliability.

For more information, please contact:

Wendy Vrooman
Director of Business Development
vrooman@dmfmedical.com
www.memsorb.com

Halifax, Nova Scotia, May 10, 2021